Arcadia Biosciences 3Q 2026: Revenue $1.62M, EPS $0.29 — 10-Q Summary
Arcadia Biosciences reported 3Q 2026 revenue of $1.62M, up 24% YoY, and net income of $1.76M, up 105% YoY. EPS was $0.29, down 53.2% YoY. The company cited strong product volumes and a $2.6M gain from warrant and option liabilities. Costs fell 14% due to a $175K tariff refund. Arcadia expressed doubt about its ability to continue as a going concern.

